1. Home
  2. ANL vs CRF Comparison

ANL vs CRF Comparison

Compare ANL & CRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$10.80

Market Cap

998.8M

Sector

N/A

ML Signal

N/A

Logo Cornerstone Total Return Fund Inc. (The)

CRF

Cornerstone Total Return Fund Inc. (The)

N/A

Current Price

$5.69

Market Cap

999.4M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ANL
CRF
Founded
2004
N/A
Country
Singapore
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
998.8M
999.4M
IPO Year
2022
1997

Fundamental Metrics

Financial Performance
Metric
ANL
CRF
Price
$10.80
$5.69
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
★ $29.50
N/A
AVG Volume (30 Days)
268.1K
★ 1.7M
Earning Date
08-14-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$243.83
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$5.43
52 Week High
$17.25
$8.16

Technical Indicators

Market Signals
Indicator
ANL
CRF
Relative Strength Index (RSI) 46.74 40.09
Support Level $8.95 $5.66
Resistance Level $11.90 $7.33
Average True Range (ATR) 0.99 0.13
MACD 0.25 0.02
Stochastic Oscillator 72.55 33.69

Price Performance

Historical Comparison
ANL
CRF

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About CRF Cornerstone Total Return Fund Inc. (The)

Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology, Health Care, Financials, Communication Services, Consumer Discretionary, Industrials, Exchange-Traded Funds, Utilities, Energy, Real Estate, and others.

Share on Social Networks: